Most Read

The US Food and Drug Administration (FDA) has approved Boehringer Ingelheim and Eli Lilly and Company’s Jardiance (empagliflozin) to treat Heart Failure with reduced Ejection Fraction (HFrEF). Jardiance

Aurinia Pharmaceuticals has bought two new pipeline assets to boost its rare autoimmune and kidney-related disease portfolio. These pipeline assets are AUR200 and AUR300 Aurinia paid an upfront

Gritstone bio and the Coalition for Epidemic Preparedness Innovations (CEPI) have signed a funding agreement to advance the development of the former’s second-generation Covid-19 vaccine programme (CORAL) against

Pfizer and its partner BioNTech have submitted the initial data of an early-stage trial to the US Food and Drug Administration (FDA) to support the authorisation of a

Merck, called MSD outside the US and Canada, has initiated a rolling submission to Health Canada for molnupiravir, an investigational oral antiviral therapy for the treatment of Covid-19.

Moderna has announced that in a new study its Covid-19 messenger ribonucleic acid (mRNA) vaccine showed durable efficacy in generating neutralising antibodies against SARS-CoV-2 variants of concern. The

The US Food and Drug Administration (FDA) has authorised additional doses of Pfizer-BioNTech and Moderna Covid-19 vaccines for certain people with compromised immune systems. The regulatory agency has

Biotherapeutics company GentiBio has raised $157m through a Series A funding round, which was led by Matrix Capital Management. The firm plans to use the proceeds from the

The US Food and Drug Administration (FDA) has declined to approve AstraZeneca and FibroGen’s new drug application (NDA) for roxadustat to treat anaemia associated with chronic kidney disease